Filing Flows › Champions Oncology (CSBR) › Q3 FY26
Champions Oncology (CSBR) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Mar 12, 2026
Champions Oncology (CSBR) reported revenue of $16.6M for the third quarter fiscal 2026 (Q3 FY26), -3% from a year earlier and +10% from the quarter before. Operating margin was -1.7%, net loss $278K (1.7% of revenue).
Champions Oncology, Q3 FY26: revenue $16.6M (-3% year over year), operating margin -1.7%, net loss $278K, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.6M | +10% | -3% |
| Operating profit | −$276K | -249% | -106% |
| Net earnings | −$278K | -204% | -106% |
| Operating cash flow | −$1.3M | — | -373% |
What changed
Revenue was $16.6M in Q3 FY26, down 3% year over year and up 10% from the previous quarter. Pharmacology services was the largest line at 98% of revenue. Other TOS revenue lost $494K year over year (down 57%), 103% of the total change.
Operating costs exceeded revenue by $276K, an operating margin of -1.7%. Total costs grew 34% against a revenue fall of 3%. The fastest-growing cost line was Sales & marketing (+48%). The quarter ended with a net loss of $278K, after a profit of $237K the previous quarter.
Operating cash flow was −$1.3M. Non-cash charges added back $341K of depreciation and amortization and $423K of share-based compensation. Working capital and other items used $1.8M. Capital expenditures of $37K exceeded it, leaving free cash flow of −$1.4M.
Questions
What was Champions Oncology's revenue in the third quarter fiscal 2026?
Champions Oncology (CSBR) reported revenue of $16.6M for the third quarter fiscal 2026 (Q3 FY26), -3% from a year earlier and +10% from the quarter before.
Was Champions Oncology profitable in the third quarter fiscal 2026?
Operating loss was $276K (-1.7% of revenue) and net loss $278K.
Source: Champions Oncology 10-Q on SEC EDGAR.